Zolgensma: fatal cases of acute liver failure (Cell and Gene Therapy Catapult – Regulatory Round-up – January 2023)
Fatal cases of acute liver failure were recently reported in patients treated with Zolgensma (onasemnogene abeparvovec), a gene therapy medicine for the treatment of spinal muscular atrophy (SMA). A direct healthcare professional communication (DHPC) will be issued by the EMA in due course. Please find details here.
See all of Catapult’s Regulatory Round-up for January 2023 here. Published on the 1st of February 2023.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (17 mai 2023). Zolgensma: fatal cases of acute liver failure (Cell and Gene Therapy Catapult – Regulatory Round-up – January 2023). ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/o6ay





